Physician profile
Darin K Bowling
NPI 1245276070
$2,093.75
in general payments reported to CMS, 2019-2025
23 companies · $48.06 in 2025
The $48.06 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $287 · 2020: $266 · 2021: $449 · 2022: $341 · 2023: $532 · 2024: $170 · 2025: $48.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $751.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $750.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $931.51 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $325.25 | 2019-2024 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $151.39 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Galt Pharmaceuticals, LLC | $91.48 | 2023 | Orphengesic Forte |
| Amarin Pharma, INC. | $76.92 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.49 | 2019-2021 | |
| Lilly USA, LLC | $67.72 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $50.04 | 2019 | |
| Abbvie INC. | $46.97 | 2020-2023 | Vraylar |
| Astellas Pharma US INC | $44.57 | 2020-2021 | |
| Pfizer INC. | $32.58 | 2019-2024 | |
| Verona Pharma, INC. | $29.54 | 2025 | Ohtuvayre |
| Takeda Pharmaceuticals U.S.A., INC. | $23.47 | 2019-2021 | |
| Insulet Corporation | $18.53 | 2024 | Omnipod |
| Astrazeneca Pharmaceuticals LP | $18.52 | 2025 | Farxiga |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.56 | 2021 | |
| Ironwood Pharmaceuticals, INC | $16.03 | 2019 | |
| Jazz Pharmaceuticals INC. | $14.61 | 2021 | |
| Esperion Therapeutics, INC. | $13.94 | 2021 | |
| Irhythm Technologies, INC. | $13.89 | 2022 | |
| Vifor Pharma, INC. | $13.81 | 2019 | |
| Amgen INC. | $11.62 | 2019 | |
| Daiichi Sankyo INC. | $11.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darin Bowling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.